HOTH THERAPEUTICS INC (HOTH) Stock Price, Forecast & Analysis
NASDAQ:HOTH • US44148G2049
HOTH Key Statistics, Chart & Performance
The current stock price of HOTH is 1.02 USD. In the past year, price decreased by -0.94%.
HOTH Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to HOTH. When comparing the yearly performance of all stocks, HOTH is a bad performer in the overall market: 72.01% of all stocks are doing better.
HOTH Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to HOTH. HOTH has a great financial health rating, but its profitability evaluates not so good.
HOTH Financial Highlights
Over the last trailing twelve months HOTH reported a non-GAAP Earnings per Share(EPS) of -1.06. The EPS increased by 20.3% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -131.58% | ||
| ROE | -147.77% | ||
| Debt/Equity | 0 |
HOTH Forecast & Estimates
7 analysts have analysed HOTH and the average price target is 5.1 USD. This implies a price increase of 400% is expected in the next year compared to the current price of 1.02.
HOTH Ownership
HOTH Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 31.45 | 954.38B | ||
| JNJ | JOHNSON & JOHNSON | 21.06 | 584.231B | ||
| MRK | MERCK & CO. INC. | 22.84 | 303.452B | ||
| PFE | PFIZER INC | 9.01 | 151.524B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 10.04 | 123.489B | ||
| ZTS | ZOETIS INC | 18.35 | 56.752B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.74 | 26.045B | ||
| VTRS | VIATRIS INC | 6.28 | 18.336B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.44 | 12.412B | ||
| AXSM | AXSOME THERAPEUTICS INC | 212 | 9.261B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About HOTH
Company Profile
Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. The company is headquartered in New York City, New York and currently employs 2 full-time employees. The company went IPO on 2019-02-15. The firm is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT), and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The firm also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004), and a treatment for obesity, and obesity-related diseases and conditions (HT-VA).
Company Info
HOTH THERAPEUTICS INC
1177 Avenue Of The Americas, 5Th Floor Suite 5066
New York City NEW YORK 10020 US
CEO: Robb Knie
Employees: 3
Phone: 16467562997
HOTH THERAPEUTICS INC / HOTH FAQ
What does HOTH do?
Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. The company is headquartered in New York City, New York and currently employs 2 full-time employees. The company went IPO on 2019-02-15. The firm is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT), and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The firm also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004), and a treatment for obesity, and obesity-related diseases and conditions (HT-VA).
What is the stock price of HOTH THERAPEUTICS INC today?
The current stock price of HOTH is 1.02 USD. The price decreased by -2.86% in the last trading session.
What is the dividend status of HOTH THERAPEUTICS INC?
HOTH does not pay a dividend.
What is the ChartMill rating of HOTH THERAPEUTICS INC stock?
HOTH has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the Price/Earnings (PE) ratio of HOTH THERAPEUTICS INC (HOTH)?
HOTH THERAPEUTICS INC (HOTH) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.06).
How many employees does HOTH THERAPEUTICS INC have?
HOTH THERAPEUTICS INC (HOTH) currently has 3 employees.